Gastric Carcinomas Drugs - Global Top Players Market Share and Ranking 2025- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > Gastric Carcinomas Drugs - Global Top Players Market Share and Ranking 2025

Gastric Carcinomas Drugs - Global Top Players Market Share and Ranking 2025

Publication Date: 2025-11-29
Report Id: 2857015
Industry: Pharma & Healthcare
Report Page: 108
Chart: 107

PDF Download

Publication Date: 2025-11-29
Report Id: 2857015
Industry: Pharma & Healthcare
Report Page: 108
Chart: 107

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Gastric Carcinomas Drugs Definition
1.2 Global Gastric Carcinomas Drugs Market Size and Forecast
1.3 China Gastric Carcinomas Drugs Market Size and Forecast
1.4 Share of China Gastric Carcinomas Drugs Market with Respect to the Global Market
1.5 Gastric Carcinomas Drugs Market Size: China VS Global Growth Rate, 2020-2031
1.6 Gastric Carcinomas Drugs Market Dynamics
1.6.1 Gastric Carcinomas Drugs Market Drivers
1.6.2 Gastric Carcinomas Drugs Market Restraints
1.6.3 Gastric Carcinomas Drugs Industry Trends
1.6.4 Gastric Carcinomas Drugs Industry Policy

2 Global Leading Players and Market Share
2.1 By Revenue of Gastric Carcinomas Drugs, Global Market Share by Company, 2020-2025
2.2 Global Gastric Carcinomas Drugs Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Gastric Carcinomas Drugs Concentration Ratio
2.4 Global Gastric Carcinomas Drugs Mergers & Acquisitions, Expansion Plans
2.5 Global Gastric Carcinomas Drugs Major Companies Product Type
2.6 Head Office and Area Served of Key Players

3 China Leading Players, Market Share and Ranking
3.1 By Revenue of Gastric Carcinomas Drugs, China Market Share by Company, 2020-2025
3.2 China Gastric Carcinomas Drugs Gastric Carcinomas Drugs Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Industry Chain Analysis
4.1 Gastric Carcinomas Drugs Industry Chain
4.2 Gastric Carcinomas Drugs Upstream Analysis
4.2.1 Gastric Carcinomas Drugs Core Raw Materials
4.2.2 Main Manufacturers of Gastric Carcinomas Drugs Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Gastric Carcinomas Drugs Production Mode
4.6 Gastric Carcinomas Drugs Procurement Model
4.7 Gastric Carcinomas Drugs Industry Sales Model and Sales Channels
4.7.1 Gastric Carcinomas Drugs Sales Model
4.7.2 Gastric Carcinomas Drugs Typical Distributors

5 Sights by Type
5.1 Gastric Carcinomas Drugs Classification by Type
5.1.1 Cytotoxic Chemotherapy
5.1.2 HER2-Targeted Therapy
5.1.3 VEGF/VEGFR-Targeted Therapy
5.1.4 PD-1/PD-L1
5.1.5 Others
5.2 by Type, Global Gastric Carcinomas Drugs Consumption Value & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Gastric Carcinomas Drugs Consumption Value, 2020-2031

6 Sights by Line of Therapy
6.1 Gastric Carcinomas Drugs Classification by Line of Therapy
6.1.1 1L
6.1.2 2L
6.1.3 3L+
6.2 by Line of Therapy, Global Gastric Carcinomas Drugs Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Line of Therapy, Global Gastric Carcinomas Drugs Consumption Value, 2020-2031

7 Sights by Drug Properties
7.1 Gastric Carcinomas Drugs Classification by Drug Properties
7.1.1 Small-molecule/Chemotherapy & TKIs
7.1.2 Biologics
7.2 by Drug Properties, Global Gastric Carcinomas Drugs Consumption Value & CAGR, 2020 VS 2024 VS 2031
7.3 by Drug Properties, Global Gastric Carcinomas Drugs Consumption Value, 2020-2031

8 Sights by Application
8.1 Gastric Carcinomas Drugs Segment by Application
8.1.1 Hospital
8.1.2 Clinic
8.2 by Application, Global Gastric Carcinomas Drugs Consumption Value & CAGR, 2020 VS 2024 VS 2031
8.3 by Application, Global Gastric Carcinomas Drugs Consumption Value, 2020-2031

9 Sales Sights by Region
9.1 By Region, Global Gastric Carcinomas Drugs Consumption Value, 2020 VS 2024 VS 2031
9.2 By Region, Global Gastric Carcinomas Drugs Consumption Value, 2020-2031
9.3 North America
9.3.1 North America Gastric Carcinomas Drugs Market Size & Forecasts, 2020-2031
9.3.2 By Country, North America Gastric Carcinomas Drugs Market Size Market Share
9.4 Europe
9.4.1 Europe Gastric Carcinomas Drugs Market Size & Forecasts, 2020-2031
9.4.2 By Country, Europe Gastric Carcinomas Drugs Market Size Market Share
9.5 Asia Pacific
9.5.1 Asia Pacific Gastric Carcinomas Drugs Market Size & Forecasts, 2020-2031
9.5.2 By Country/Region, Asia Pacific Gastric Carcinomas Drugs Market Size Market Share
9.6 South America
9.6.1 South AmericaGastric Carcinomas Drugs Market Size & Forecasts, 2020-2031
9.6.2 By Country, South America Gastric Carcinomas Drugs Market Size Market Share
9.7 Middle East & Africa

10 Sales Sights by Country Level
10.1 By Country, Global Gastric Carcinomas Drugs Market Size & CAGR, 2020 VS 2024 VS 2031
10.2 By Country, Global Gastric Carcinomas Drugs Consumption Value, 2020-2031
10.3 United States
10.3.1 United States Gastric Carcinomas Drugs Market Size, 2020-2031
10.3.2 by Type, United States Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.3.3 by Application, United States Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.4 Europe
10.4.1 Europe Gastric Carcinomas Drugs Market Size, 2020-2031
10.4.2 by Type, Europe Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.4.3 by Application, Europe Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.5 China
10.5.1 China Gastric Carcinomas Drugs Market Size, 2020-2031
10.5.2 by Type, China Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.5.3 by Application, China Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.6 Japan
10.6.1 Japan Gastric Carcinomas Drugs Market Size, 2020-2031
10.6.2 by Type, Japan Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.6.3 by Application, Japan Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.7 South Korea
10.7.1 South Korea Gastric Carcinomas Drugs Market Size, 2020-2031
10.7.2 by Type, South Korea Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.7.3 by Application, South Korea Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.8 Southeast Asia
10.8.1 Southeast Asia Gastric Carcinomas Drugs Market Size, 2020-2031
10.8.2 by Type, Southeast Asia Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.8.3 by Application, Southeast Asia Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.9 India
10.9.1 India Gastric Carcinomas Drugs Market Size, 2020-2031
10.9.2 by Type, India Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.9.3 by Application, India Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.10 Middle East & Africa
10.10.1 Middle East & Africa Gastric Carcinomas Drugs Market Size, 2020-2031
10.10.2 by Type, Middle East & Africa Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031
10.10.3 by Application, Middle East & Africa Gastric Carcinomas Drugs Consumption Value Market Share, 2024 VS 2031

11 Company Profile
11.1 Taiho Pharmaceutical
11.1.1 Taiho Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
11.1.2 Taiho Pharmaceutical Company Profile and Main Business
11.1.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Models, Specifications, and Application
11.1.4 Taiho Pharmaceutical Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.1.5 Taiho Pharmaceutical Recent Developments
11.2 Genentech (Roche)
11.2.1 Genentech (Roche) Company Information, Head Office, Market Area, and Industry Position
11.2.2 Genentech (Roche) Company Profile and Main Business
11.2.3 Genentech (Roche) Gastric Carcinomas Drugs Models, Specifications, and Application
11.2.4 Genentech (Roche) Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.2.5 Genentech (Roche) Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Information, Head Office, Market Area, and Industry Position
11.3.2 Sanofi Company Profile and Main Business
11.3.3 Sanofi Gastric Carcinomas Drugs Models, Specifications, and Application
11.3.4 Sanofi Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.3.5 Sanofi Recent Developments
11.4 Eli Lilly
11.4.1 Eli Lilly Company Information, Head Office, Market Area, and Industry Position
11.4.2 Eli Lilly Company Profile and Main Business
11.4.3 Eli Lilly Gastric Carcinomas Drugs Models, Specifications, and Application
11.4.4 Eli Lilly Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.4.5 Eli Lilly Recent Developments
11.5 Astellas Pharma
11.5.1 Astellas Pharma Company Information, Head Office, Market Area, and Industry Position
11.5.2 Astellas Pharma Company Profile and Main Business
11.5.3 Astellas Pharma Gastric Carcinomas Drugs Models, Specifications, and Application
11.5.4 Astellas Pharma Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.5.5 Astellas Pharma Recent Developments
11.6 Bristol Myers Squibb
11.6.1 Bristol Myers Squibb Company Information, Head Office, Market Area, and Industry Position
11.6.2 Bristol Myers Squibb Company Profile and Main Business
11.6.3 Bristol Myers Squibb Gastric Carcinomas Drugs Models, Specifications, and Application
11.6.4 Bristol Myers Squibb Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.6.5 Bristol Myers Squibb Recent Developments
11.7 Merck & Co., Inc
11.7.1 Merck & Co., Inc Company Information, Head Office, Market Area, and Industry Position
11.7.2 Merck & Co., Inc Company Profile and Main Business
11.7.3 Merck & Co., Inc Gastric Carcinomas Drugs Models, Specifications, and Application
11.7.4 Merck & Co., Inc Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.7.5 Merck & Co., Inc Recent Developments
11.8 BeiGene
11.8.1 BeiGene Company Information, Head Office, Market Area, and Industry Position
11.8.2 BeiGene Company Profile and Main Business
11.8.3 BeiGene Gastric Carcinomas Drugs Models, Specifications, and Application
11.8.4 BeiGene Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.8.5 BeiGene Recent Developments
11.9 Jiangsu Hengrui
11.9.1 Jiangsu Hengrui Company Information, Head Office, Market Area, and Industry Position
11.9.2 Jiangsu Hengrui Company Profile and Main Business
11.9.3 Jiangsu Hengrui Gastric Carcinomas Drugs Models, Specifications, and Application
11.9.4 Jiangsu Hengrui Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.9.5 Jiangsu Hengrui Recent Developments
11.10 RemeGen
11.10.1 RemeGen Company Information, Head Office, Market Area, and Industry Position
11.10.2 RemeGen Company Profile and Main Business
11.10.3 RemeGen Gastric Carcinomas Drugs Models, Specifications, and Application
11.10.4 RemeGen Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.10.5 RemeGen Recent Developments
11.11 Daiichi Sankyo + AstraZeneca
11.11.1 Daiichi Sankyo + AstraZeneca Company Information, Head Office, Market Area, and Industry Position
11.11.2 Daiichi Sankyo + AstraZeneca Company Profile and Main Business
11.11.3 Daiichi Sankyo + AstraZeneca Gastric Carcinomas Drugs Models, Specifications, and Application
11.11.4 Daiichi Sankyo + AstraZeneca Gastric Carcinomas Drugs Revenue and Gross Margin, 2020-2025
11.11.5 Daiichi Sankyo + AstraZeneca Recent Developments

12 Conclusion

13 Appendix
13.1 Research Methodology
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Market Estimation Model
13.4 Disclaimer

According to YH Research, the global market for Gastric Carcinomas Drugs should grow from US$ 5255 million in 2024 to US$ 11445 million by 2031, with a CAGR of 11.8% for the period of 2025-2031.

From a product-type perspective, gastric cancer therapies can be broadly categorized into chemical drugs (including traditional cytotoxic chemotherapies and small-molecule targeted agents) and biologics (monoclonal antibodies, antibody–drug conjugates and immune checkpoint inhibitors, etc.). The former, represented by 5-FU, capecitabine, S-1, platinum agents and small-molecule TKIs such as apatinib, still constitute the backbone of gastric cancer treatment worldwide; the latter, including HER2-targeted antibodies/ADCs, VEGFR-2 antibodies, PD-1/PD-L1 inhibitors and CLDN18.2-targeted antibodies, provides more precise, biomarker-driven options for selected patient subgroups.

Gastric Carcinomas Drugs

According to YH Research, the global market for Gastric Carcinomas Drugs should grow from US$ 5255 million in 2024 to US$ 11445 million by 2031, with a CAGR of 11.8% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

Gastric cancer therapeutics are rapidly evolving from traditional cytotoxic chemotherapy toward an integrated “chemicals + biologics + precision segmentation” solution market. On the global stage, Keytruda® (pembrolizumab) from Merck, a PD-1 inhibitor, has been approved in Europe and the US in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma with PD-L1 positivity and HER2 negativity, significantly improving overall survival and response rates. At the same time, Herceptin® (trastuzumab) from Roche combined with chemotherapy has become the standard first-line regimen for HER2-positive metastatic gastric and GEJ cancer, providing a clearly defined benefit pathway for the approximately 15–20% of patients with HER2 overexpression.

In China, domestic innovative biopharma companies are penetrating gastric cancer sub-segments through differentiated pipelines. Apatinib (Aitan®) from Jiangsu Hengrui Medicine, a small-molecule VEGFR-2 TKI, is the first targeted agent approved in China for third-line and later treatment of advanced gastric or GEJ adenocarcinoma after failure of at least two prior systemic regimens, providing many late-stage patients with an oral maintenance and “last-resort” option. Disitamab vedotin (RC48, Aidixi®) from RemeGen, a HER2-targeted ADC, has been conditionally approved by the NMPA for locally advanced or metastatic HER2-overexpressing gastric or GEJ cancer previously treated with multiple lines of systemic therapy, becoming the first domestically developed ADC to be approved with gastric cancer as its lead indication. Together with Tevimbra® (tislelizumab) from BeiGene, a PD-1 antibody already approved overseas for first-line gastric cancer, Chinese companies are building a comprehensive treatment continuum from first- to third-line and beyond through a combination strategy of “chemotherapy backbone + small-molecule targeted therapy + PD-1 inhibitors + ADCs,” finely covering different subpopulations such as HER2-positive, VEGFR-driven, and PD-L1-positive patients. Overall, the gastric cancer drug market is increasingly characterized by a pattern in which leading multinational companies define the molecular-segmented standards, while domestic innovators rapidly fill gaps and create new clinical scenarios, and in the coming years, combination and sequential regimens centered on HER2, VEGFR, PD-1/PD-L1 and CLDN18.2 will continue to raise barriers to entry and represent the core growth drivers for investment and industrial deployment.

This report studies and analyses global Gastric Carcinomas Drugs status and future trends, to help determine the Gastric Carcinomas Drugs market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Gastric Carcinomas Drugs, and provides market size (US$ million) and Year-over-Year growth, considering 2023 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Gastric Carcinomas Drugs market size, history data 2019-2024, and forecast data 2025 -2030, (US$ million)
(2) Global Gastric Carcinomas Drugs by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(3) China Gastric Carcinomas Drugs by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(4) Global Gastric Carcinomas Drugs key consuming regions, consumption value and demand structure
(5) Gastric Carcinomas Drugs industry chains, upstream, midstream and downstream
Market segment by players, this report covers
    Taiho Pharmaceutical
    Genentech (Roche)
    Sanofi
    Eli Lilly
    Astellas Pharma
    Bristol Myers Squibb
    Merck & Co., Inc
    BeiGene
    Jiangsu Hengrui
    RemeGen
    Daiichi Sankyo + AstraZeneca

Market segment by Type, covers
    Cytotoxic Chemotherapy
    HER2-Targeted Therapy
    VEGF/VEGFR-Targeted Therapy
    PD-1/PD-L1
    Others

Market segment by Application, can be divided into
    Hospital
    Clinic

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Gastric Carcinomas Drugs product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Gastric Carcinomas Drugs market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 3: China Gastric Carcinomas Drugs market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 4: Gastric Carcinomas Drugs industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2019-2030
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2019-2030
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2019-2030
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2019-2030
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions